Resalis Therapeutics Announces Initiation of Phase 1 Clinical Trial for RES-010 in Obesity

Dec 03, 2024 Resalis Therapeutics Announces Initiation of Phase 1 Clinical Trial for RES-010 in Obesity View PDF

Resalis Therapeutics Gains Strategic Equity Investment from Sanofi

Oct 28, 2024 Resalis Therapeutics Gains Strategic Equity Investment from Sanofi View PDF

Resalis Therapeutics Appoints Almut Nitsche as Chief Medical and Development Officer

Feb 1, 2024 Resalis Therapeutics Appoints Almut Nitsche as Chief Medical and Development Officer View PDF

Resalis Therapeutics Raises €10 Million Series A to Complete First Clinical Trial for RES-010 in Obesity

Jan 4, 2024 Resalis Therapeutics Raises €10 Million Series A to Complete First Clinical Trial for RES-010 in Obesity View PDF

Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases

Feb 22, 2023 Resalis Therapeutics Announces Seed Financing of €10 Million to Fund Non-coding RNA-based Therapeutics for Metabolic Diseases View PDF